TelyRx Posts $23.1M Q3 Revenue, Widens Loss

The company's third-quarter revenue rose sharply from a year earlier while its net loss grew.

Updated on Nov. 9, 2026 in Economic Indicators

Photograph of a shrink-wrapped pallet of sealed cardboard cartons standing alone in an empty concrete warehouse bay under soft overhead daylight.
TelyRx Holdings reported $23.1 million in third-quarter revenue, nearly double a year earlier, while its net loss widened to $2.8 million. AI Illustration. Upload story photo >

TelyRx Holdings Inc. reported $23.078 million in third-quarter 2026 revenue, up from $12.337 million a year earlier. The company posted a $2.829 million net loss, compared with a $1.058 million loss in the same period of 2025.

Why it matters

The results show revenue nearly doubling while losses widened, a pattern that puts the company's path to profitability in focus for investors and analysts. Gross margin improved to 60% from 56%, indicating stronger profitability per dollar of sales even as operating costs rose.

The figures are unaudited interim results from the company's third-quarter 2026 filing, showing revenue of $23.078 million against $12.337 million a year earlier and a net loss of $2.829 million versus $1.058 million. Management did not indicate in these results whether spending increases on marketing, infrastructure and personnel will persist into coming quarters.

The players

TelyRx Holdings Inc.

TelyRx Holdings Inc. is the publicly reporting company whose third-quarter 2026 financial results are the subject of this report.

The details

TelyRx attributed its larger operating loss to about $1 million in noncash stock-based compensation along with higher advertising and marketing investment and increased spending on infrastructure, personnel and operations. Revenue included $17.4 million from recurring customers and $5.7 million from new customers, and adjusted EBITDA was a $1.277 million loss compared with a $3.201 million loss in the prior quarter.

Timeline

  1. • Third quarter 2025 ended September 30, 2025, establishing the year-earlier comparison.

  2. • Third quarter 2026 ended September 30, 2026, with the reported results.

  3. • Unaudited interim statements were approved and results announced November 5, 2026.

Market Dynamics

Compared with its own third-quarter 2025 baseline, TelyRx nearly doubled revenue to $23.078 million while its net loss rose from $1.058 million to $2.829 million. The pattern of rapid top-line growth alongside widening losses reflects the spending choices reported in this filing rather than a change in gross margin direction, which improved from 56% to 60%.

For investors holding TelyRx shares, the widening net loss and $0.06 loss per share are the figures to weigh against the company's revenue growth. The results show how a fast-growing company can still report increasing losses when it spends heavily on marketing and infrastructure.

The takeaway

Strong revenue growth does not guarantee narrowing losses, so investors often watch margin trends and spending plans alongside top-line results. TelyRx's improved gross margin is one signal to track in its upcoming filings.

Further reading

Explore more economic indicators to see how company results fit into broader national data trends.

Source note: This article includes information reported by TokenPost.